For other inquiries, please contact us here:


Mandatory Information

Hepa-Merz® Granulate 3000, Hepa-Merz® Granulate 6000, Hepa-Merz® Infusion-concentrate

Active substance: L-ornithine- L-aspartate

Indications: Treatment of concomitant disease and sequelae due to impaired detoxification activity (e.g. in cirrhosis of the liver) with the symptoms of latent and manifest hepatic encephalopathy.

For risks and side effects please read package insert and ask your doctor or pharmacist.

Warnings: Hepa-Merz® Granulate 3000, Hepa-Merz® Granulate 6000: Contains orange yellow S (E110), fructose. Do not take this medicine with hereditary problems of fructose intolerance.

Version July 2019

Merz Pharmaceuticals GmbH, 60048 Frankfurt



We care about what is important.

Upper Polygon
Lower Polygone

The main function of our metabolic system is to provide sufficient energy to the entire body. In this context, the liver regulates our protein, fat and sugar metabolism as well as mineral, vitamin and hormone balance and is therefore crucial for maintaining our bodily functions.

If the liver is damaged or disordered due to a disease or malnutrition, the consequences for health can be serious. Liver disease and the resulting changes in blood composition can lead to gallstones or even brain dysfunction. In particular, chronic liver diseases (CLD) represent a significant public health concern worldwide.

CLD, leading from fatty liver to severe neurological complications (such as hepatic encephalopathy, HE), can be caused by viruses, metabolic dysfunction, autoimmune diseases, and alcoholism. The continuous process of inflammation and degeneration of the liver eventually leads to liver fibrosis (formation of scar tissue), which results in a loss of function in the affected parts of the liver.

Therefore, CLD requires immediate treatment in order to prevent aggravation and the development of liver cirrhosis, the full impairment of liver function due to liver fibrosis. Thus, it is important to treat liver disease with an appropriate therapy to prevent further liver damage and decrease the symptom burden for liver patients and improve their quality of life. That’s why Merz Therapeutics supports patients with treatment options in this area.

Learn more about CLD

Packshot Hepa-Merz® (L-ornithine L-aspartate)

Hepa-Merz® (L-ornithine L-aspartate)

For the treatment of patients with chronic liver disease (CLD), we have developed a combination of two amino acids, L-ornithine and L-aspartate (LOLA). These active ingredients occur naturally in the body and play an important role in liver metabolism and detoxification of ammonia in the blood. Hepa-Merz is suitable especially in patients with insufficient hepatic detoxification (e.g. in liver cirrhosis) and its complications.